Share this article

Seer has been established to leverage proteomic profiling to facilitate early detection of cancer and neurological disorders.

The company developed the Proteograph platform to ensure fast, cost-effective, broad-scale and accurate proteomic profiling for many patients.

Seer applies machine-learning algorithms to analyse the resulting high volume of proteomic data for generating population-level, molecular insights into the disease.

The insights will be used to develop liquid biopsy tests to identify diseases at early, pre-symptomatic stages.

Seer co-founder and CEO Omid Farokhzad said: “Our Proteograph platform allows for the first-ever generation of proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, and affording us comprehensive insights to deliver first-in-class liquid biopsy products with a goal of achieving very early disease detection.”

Using a small biological sample, the Proteograph platform utilises a variety of technologies such as nanotechnology, protein chemistry, and machine learning for proteomic profiling.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It is said to capture and analyse numerous data points from proteins with high accuracy. This approach provides a biomolecular fingerprint of health status and disease for each individual.

Seer expects the proteomic information to aid early detection and treatment with existing therapies. It will also facilitate the discovery and development of new therapies.

“Seer expects the proteomic information to aid early detection and treatment with existing therapies.”

Seer co-founder and director Robert Langer said: “The proteome, remarkably, can give us insights into the future of human health. But, accessing this data reproducibly and accurately, and then translating it into practical applications, has proven to be challenging.

“Seer’s Proteograph technology and novel approach have the potential to overcome these challenges.”

Seer has raised $36m in series A and B financing rounds led by Maverick Ventures and Invus, with participation from other investors.

The company is using the funds to advance its Proteograph platform, expand the proteomic database, further its discovery programmes and develop liquid biopsy products.

It plans to develop strategic partnerships to develop products using the Proteograph platform.